The reason why its not scaling is because change is too complicated for health systems, theres too many dependencies, and were lacking a lot of the platform and governance infrastructure to actually scale these one-by-one use cases
The Oyikey SMGT GLP-1 Nano Microneedle Patch has been generating a lot of buzz lately as a potential game-changer in the treatment of obesity, diabetes, and cardiovascular diseases
Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: evidence from a systematic review and meta-analysis
When were talking about 180,000 enrollees, children and adults, thats over 90,000 women who are Medicaid beneficiaries who may be living with obesity and could take advantage of receiving the obesity management medications basically to stem those comorbidities that are associated with living with obesity, Millicent Gorham, CEO of the Alliance for Womens Health and Prevention, said in a phone interview with the Bulletin Thursday